-
Mashup Score: 10The Moral Crisis of America’s Doctors - 11 month(s) ago
The corporatization of health care has changed the practice of medicine, causing many physicians to feel alienated from their work.
Source: www.nytimes.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1next frontier: enter PD-1 and exit PET scans? - 12 month(s) ago
In this issue of Blood, Lynch et al present compelling results of a single-arm study of concurrent pembrolizumab, doxorubicin (Adriamycin), vinblastine, and dac
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @Rcl14L: Editorial by @matthew_mei and Alex Herrera https://t.co/N1EtKju7AH
-
-
Mashup Score: 2
Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma – Full Text View.
Source: clinicaltrials.govCategories: Hem/Oncs, Latest HeadlinesTweet-
@Eddie_Cliff Tricky given how well DA-R-EPOCH (and even R-CHOP) works. There is an ongoing frontline trial of R-CHOP / DA-R-EPOCH +/- nivo through the NCI https://t.co/oyqTvWkMs6
-
-
Mashup Score: 1Update on IMBRUVICA® (ibrutinib) U.S. Accelerated Approvals for Mantle Cell Lymphoma and Marginal Zone Lymphoma Indications | AbbVie News Center - 1 year(s) ago
NORTH CHICAGO, Ill., April 6, 2023 – AbbVie (NYSE: ABBV) announced today the intent to voluntarily withdraw, in the U.S., accelerated IMBRUVICA® (ibrutinib) approvals for patients with the blood cancers mantle cell lymphoma (MCL) who have received at least one prior therapy and with marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based…
Source: news.abbvie.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @jeff_sharman: Didn’t see this coming- ibrutinib accelerated approval going away in mcl and mzl…. Wow! https://t.co/16jynvo65o
-
-
Mashup Score: 1
Key Points. Concurrent pembrolizumab and AVD was safe and effective in untreated Hodgkin lymphoma without clinically significant treatment delays.PET CR rates w
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @moh7madhomod: Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma https://t.co/P73GidoyAO https://t.co/kbapQNna…
-
-
Mashup Score: 69
In this observational study, targeted deep DNA sequencing was performed to test the hypothesis that detection of specific residual AML-associated variants in the blood of patients in first remission prior to allogeneic hematopoietic cell transplant would be associated with higher rates of relapse…
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @DrChrisHourigan: DNA Sequencing to Detect Residual Disease for Acute Myeloid Leukemia https://t.co/8KevMvCkCE via @JAMA_current part of…
-
-
Mashup Score: 47
HCA Healthcare is facing accusations that it’s making billions while slashing staffing to dangerously low levels. NBC News’ Cynthia McFadden spoke with a dozen current and former mission employees who all say that under HCA patient care has suffered.
Source: NBC NewsCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @NBCNightlyNews: Last month, investigated claims against America’s largest hospital corporation, HCA: https://t.co/LzQRuyy6ZH One neur…
-
-
Mashup Score: 0Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma - 1 year(s) ago
Key Points. Second-line axi-cel is provisionally cost-effective in selected primary refractory/early relapsed DLBCL patients at a WTP of $100 000 per QALY.The c
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
@RahulBanerjeeMD @UCSFCancer @cityofhope @SwethaKMD @BloodJournal @Eddie_Cliff Correction: two @BloodJournal papers. https://t.co/mK5COrPNlH
-
-
Mashup Score: 1Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma - 1 year(s) ago
Key Points. R-B with ASCT and MR is a feasible first-line strategy for younger, transplant-eligible patients with MCL.R-B with ASCT and MR achieves outcomes com
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
@AaronGoodman33 And BR + ASCT looks similar to R-CHOP / R-DHAP + ASCT ... by the transitive property then BR + ibrutinib wins right? So SHINE after all? (Btw this is in jest obviously) https://t.co/KQS9Cxbfig
-
-
Mashup Score: 0Cellular therapy: Great promise, but at what cost? - 1 year(s) ago
The introduction of chimeric antigen receptor T cell (CAR-T) therapy has been transformative in hematological malignancies. In the US, there are now 6 FDA-approved products across 5 malignancies; acute lymphoblastic leukemia, diffuse large B cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, and multiple myeloma. These are highly potent treatments that are effective in patients…
Source: Molecular TherapyCategories: Hem/Oncs, Latest HeadlinesTweet-
Great collaboration with @MichaelDJain and @lisa_masucci - our opinion peace in Molecular Therapy re: the high cost of cellular therapies. https://t.co/EmoNt7fb9p
-
RT @JReinerMD: A long and important read about moral injury in medicine. https://t.co/eht8qSzDOU